JP Morgan Chase
GPCR icon

JP Morgan Chase’s Structure Therapeutics GPCR Stock Holding History

JP Morgan Chase’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.35M Buy
212,803
+199,847
+1,543% +$13.7M ﹤0.01% 2749
2025
Q4 		$901K Sell
12,956
-45,192
-78% -$1.85M ﹤0.01% 4677
2025
Q3 		$1.63M Buy
58,148
+15,706
+37% +$313K ﹤0.01% 4234
2025
Q2 		$880K Sell
42,442
-91,797
-68% -$2.02M ﹤0.01% 4457
2025
Q1 		$2.32M Buy
134,239
+101,924
+315% +$2.5M ﹤0.01% 3766
2024
Q4 		$876K Sell
32,315
-1,621
-5% -$57.5K ﹤0.01% 4721
2024
Q3 		$1.49M Buy
33,936
+25,500
+302% +$986K ﹤0.01% 4228
2024
Q2 		$331K Sell
8,436
-15,995
-65% -$657K ﹤0.01% 4901
2024
Q1 		$1.05M Buy
24,431
+16,585
+211% +$699K ﹤0.01% 4320
2023
Q4 		$320K Sell
7,846
-31,713
-80% -$1.82M ﹤0.01% 5064
2023
Q3 		$1.99M Buy
+39,559
New +$1.27M ﹤0.01% 3540

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

JP Morgan Chase's GPCR Position: Q1 2026 in Review

JP Morgan Chase increased its Structure Therapeutics (GPCR) stake by 1,543% in Q1 2026, buying an estimated $13.7M and bringing the position to 212,803 shares worth $9.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

JP Morgan Chase first reported a position in GPCR in Q3 2023 and has held it in 11 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • JP Morgan Chase held 212,803 shares of Structure Therapeutics worth $9.35M as of Q1 2026.
  • JP Morgan Chase bought 199,847 Structure Therapeutics shares in Q1 2026, an estimated $13.7M.
  • Structure Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2749 holding.
  • JP Morgan Chase first reported a position in Structure Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.